All In Biotech

Drug Trial Radar · NCT01219855

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism

Last checked: Nov 19, 2026Latest source record: Aug 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

78

Actual

Start

Oct 2010

Primary completion

Nov 2011

Study completion Nov 2011

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Oct 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).

Conditions

  • Chronic Kidney Disease
  • Secondary Hyperparathyroidism
  • Vitamin D Insufficiency

Interventions

  • Cohort 1 CTAP101 Capsules- 60µgDrug

    60µg of CTAP101 capsules given once daily for 42 days.

  • Cohort 1 CTAP101 Capsules - 90µgDrug

    90µg of CTAP101 capsules given once daily for 42 days.

  • Cohort 1 Matching Sugar CapsuleDrug

    Placebo capsules given once daily for 42 days.

  • Cohort 2 CTAP101 Capsules - 30µgDrug

    30µg of CTAP101 capsules given once daily for 42 days.

  • Cohort 2 Matching Sugar CapsuleDrug

    Placebo capsules given once daily for 42 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).Time frame: 6 weeks
  2. Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OPKO Health, Inc

    Bannockburn, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.